Abemaciclib + MK-6482

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Clear Cell Renal Cell Carcinoma

Conditions

Clear Cell Renal Cell Carcinoma

Trial Timeline

Dec 31, 2020 → Aug 4, 2024

NCT ID

NCT04627064

About Abemaciclib + MK-6482

Abemaciclib + MK-6482 is a phase 1 stage product being developed by Eli Lilly for Clear Cell Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04627064. Target conditions include Clear Cell Renal Cell Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04627064	Phase 1	Completed	Dec 31, 2020	Aug 4, 2024	Clear Cell Renal Cell Carcinoma

Competing Products

20 competing products in Clear Cell Renal Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Pembrolizumab + Cabozantinib	Genenta Science	Phase 1/2	33
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
Cefiderocol	Shionogi	Approved	85
fospropofol + fospropofol + fospropofol + fospropofol	Eisai	Pre-clinical	23
lenvatinib + everolimus	Eisai	Phase 2	52
Nivolumab + Everolimus	Ono Pharmaceutical	Phase 3	77
LY2510924 + Sunitinib	Eli Lilly	Phase 2	52
nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)	Sumitomo Pharma	Approved	85
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	52
Placebo + ABBV-8E12	AbbVie	Phase 2	52
ABBV-8E12	AbbVie	Phase 1	33
Savolitinib + MEDI4736 + Tremelimumab	AstraZeneca	Phase 2	52
Ceralasertib + Olaparib + Durvalumab	AstraZeneca	Phase 2	52
Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin Hydrochloride	AstraZeneca	Phase 3	77
AZD8701 + Durvalumab	AstraZeneca	Phase 1	33
AZD2014 + Everolimus	AstraZeneca	Phase 2	52
Volrustomig + Casdatifan + Nivolumab + Ipilimumab	AstraZeneca	Phase 3	77
HFO-1234ze(E) + HFA-134a	AstraZeneca	Phase 3	77
Pembrolizumab plus denosumab	Merck	Phase 2	52
MK-3475 + Bevacizumab + MK-3475 + Bevacizumab	Merck	Phase 1/2	41

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved